Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Tegafur-uracil in Oral Cavity SCC with Extracapsular Spreading
NCT03121313Phase 2Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Feb 2015
- Primary completion
- May 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in oral cavity squamous cell carcinoma (OCSCC), sponsored by Chang Gung Memorial Hospital. Primary endpoint: 2-year distant failure rate. Status: unknown.
02
Drugs
tegafur
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT03121313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121313.